{"id":"mfolfox6-bevacizumab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The oxaliplatin, 5-fluorouracil, and leucovorin combination works by interfering with DNA replication and cell division, while bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis.","oneSentence":"mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:10.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07228832","phase":"PHASE3","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Summit Therapeutics","startDate":"2025-11-18","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":600},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT05919264","phase":"PHASE1, PHASE2","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Parabilis Medicines, Inc.","startDate":"2023-05-23","conditions":"Cancer, Colorectal Cancer, Solid Tumor","enrollment":575},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT06268015","phase":"PHASE2","title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas DeVito, MD","startDate":"2024-11-18","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT07362836","phase":"PHASE3","title":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-31","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT06791512","phase":"PHASE3","title":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-01-18","conditions":"Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum","enrollment":166},{"nctId":"NCT06934538","phase":"PHASE1, PHASE2","title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Brenus Pharma","startDate":"2025-06-17","conditions":"Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer","enrollment":90},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT04660812","phase":"PHASE1, PHASE2","title":"An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-05-10","conditions":"Metastatic Colorectal Cancer","enrollment":227},{"nctId":"NCT05052099","phase":"PHASE1, PHASE2","title":"Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2021-10-22","conditions":"Biliary Tract Cancer","enrollment":20},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT02671435","phase":"PHASE1, PHASE2","title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2016-02-22","conditions":"Advanced Solid Tumors","enrollment":383},{"nctId":"NCT06908031","phase":"PHASE2","title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-04-02","conditions":"Rectal Adenocarcinoma, High-Risk Cancer, MSS","enrollment":49},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT04761614","phase":"PHASE1","title":"Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Ning Jin","startDate":"2021-04-02","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":13},{"nctId":"NCT04952753","phase":"PHASE2","title":"Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Metastatic Colorectal Cancer","enrollment":204},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT04895137","phase":"PHASE2","title":"mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-05-01","conditions":"Colorectal Cancer, Immunotherapy","enrollment":42},{"nctId":"NCT03511963","phase":"PHASE3","title":"A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2018-04-09","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":677},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06493760","phase":"PHASE2","title":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06590259","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-03-12","conditions":"Colorectal Cancer Liver Metastasis","enrollment":20},{"nctId":"NCT06491355","phase":"PHASE2","title":"First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-07-01","conditions":"Efficacy, Self, Safety Issues, Colo-rectal Cancer","enrollment":72},{"nctId":"NCT06415851","phase":"PHASE2","title":"Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab","status":"NOT_YET_RECRUITING","sponsor":"Zhangfa Song","startDate":"2024-06-01","conditions":"Metastatic Colorectal Cancer, MSS","enrollment":36},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT00321828","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-03","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT05111860","phase":"PHASE1, PHASE2","title":"Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy","status":"RECRUITING","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2022-11-01","conditions":"Neoadjuvant Treatment, Rectal Cancer, Bevacizumab","enrollment":20},{"nctId":"NCT03135652","phase":"PHASE2","title":"Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation","status":"WITHDRAWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-08-01","conditions":"Radiotherapy, Colorectal Cancer, Liver Metastases","enrollment":""},{"nctId":"NCT03439462","phase":"PHASE1, PHASE2","title":"Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-07-01","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT04310176","phase":"PHASE2","title":"Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-05-24","conditions":"Ras-mutated Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT02394795","phase":"PHASE3","title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":823},{"nctId":"NCT03750786","phase":"PHASE3","title":"A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Isofol Medical AB","startDate":"2018-12-18","conditions":"Colo-rectal Cancer","enrollment":490},{"nctId":"NCT01468623","phase":"PHASE4","title":"Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6","status":"TERMINATED","sponsor":"Myriad Genetic Laboratories, Inc.","startDate":"2011-09","conditions":"Colorectal Cancer, Metastatic","enrollment":51},{"nctId":"NCT02969681","phase":"PHASE3","title":"Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-01","conditions":"Colorectal Neoplasms","enrollment":442},{"nctId":"NCT01718873","phase":"PHASE3","title":"Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2012-05","conditions":"Colorectal Cancer","enrollment":230},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05652894","phase":"PHASE3","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-20","conditions":"Metastatic Colorectal Cancer","enrollment":190},{"nctId":"NCT00819780","phase":"PHASE2","title":"PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-04-24","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":285},{"nctId":"NCT01307878","phase":"PHASE3","title":"New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-06","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":320},{"nctId":"NCT05378867","phase":"PHASE3","title":"A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2022-08-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":126},{"nctId":"NCT00193219","phase":"PHASE2","title":"Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2005-07","conditions":"Colon Cancer","enrollment":36},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT00308516","phase":"PHASE2","title":"5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-03","conditions":"Rectal Cancer, Cancer of the Rectum, Colorectal Cancer","enrollment":66},{"nctId":"NCT03176264","phase":"PHASE1","title":"PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-25","conditions":"Metastatic Colorectal Cancer","enrollment":1},{"nctId":"NCT04781270","phase":"PHASE3","title":"mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-04-15","conditions":"Colorectal Carcinoma, Liver Metastases","enrollment":308},{"nctId":"NCT01327612","phase":"PHASE2","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03-03","conditions":"Advanced Solid Tumors, Carcinoid, Colorectal Cancer","enrollment":12},{"nctId":"NCT02244632","phase":"PHASE1, PHASE2","title":"Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer","status":"COMPLETED","sponsor":"Isofol Medical AB","startDate":"2014-09","conditions":"Colorectal Neoplasm","enrollment":105},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT02648711","phase":"PHASE1","title":"Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2015-10","conditions":"Solid Tumors","enrollment":41},{"nctId":"NCT02141295","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-30","conditions":"Colorectal Cancer","enrollment":197},{"nctId":"NCT02339116","phase":"PHASE3","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2015-02-26","conditions":"Metastatic Colorectal Cancer","enrollment":654},{"nctId":"NCT01972490","phase":"PHASE4","title":"Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases","status":"COMPLETED","sponsor":"Xu jianmin","startDate":"2013-10","conditions":"Colorectal Neoplasms","enrollment":241},{"nctId":"NCT02776683","phase":"PHASE3","title":"Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-06-08","conditions":"Colorectal Neoplasms","enrollment":123},{"nctId":"NCT02331927","phase":"PHASE2","title":"PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"University of Ulm","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":150},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT00096278","phase":"PHASE3","title":"Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09-15","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2710},{"nctId":"NCT01640405","phase":"PHASE3","title":"Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-07","conditions":"Metastatic Colorectal Cancer","enrollment":350},{"nctId":"NCT00724503","phase":"NA","title":"FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer","status":"COMPLETED","sponsor":"Sirtex Medical","startDate":"2006-08","conditions":"Colorectal Cancer, Colorectal Carcinoma, Liver Metastases","enrollment":530},{"nctId":"NCT01588990","phase":"PHASE4","title":"A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-26","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT03686254","phase":"PHASE2, PHASE3","title":"The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-07-16","conditions":"Colorectal Neoplasms Malignant","enrollment":160},{"nctId":"NCT01836653","phase":"PHASE2","title":"Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer","enrollment":122},{"nctId":"NCT01834014","phase":"NA","title":"Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Metastasis, Colorectal Cancer","enrollment":110},{"nctId":"NCT01383707","phase":"PHASE2","title":"A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-12","conditions":"Colorectal Cancer","enrollment":77},{"nctId":"NCT02413853","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2015-11","conditions":"Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":""},{"nctId":"NCT01332604","phase":"PHASE1","title":"GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-07","conditions":"Solid Cancers","enrollment":41},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT00778102","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT01338558","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2011-06","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT01399684","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-11","conditions":"Metastatic Colorectal Cancer","enrollment":127},{"nctId":"NCT01374425","phase":"PHASE2","title":"Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-08","conditions":"Colorectal Cancer","enrollment":376},{"nctId":"NCT01164215","phase":"PHASE1","title":"Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-02","conditions":"Colorectal Cancer, Diarrhea, Neutropenia","enrollment":76},{"nctId":"NCT01658033","phase":"PHASE2","title":"Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-05","conditions":"Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT01478594","phase":"PHASE2","title":"A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy","status":"COMPLETED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2011-12","conditions":"Colorectal Cancer","enrollment":265},{"nctId":"NCT00904839","phase":"PHASE2","title":"BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-05","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT00881504","phase":"PHASE2","title":"A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-06","conditions":"Biliary Tract Cancer","enrollment":9},{"nctId":"NCT00625651","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10","conditions":"Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer","enrollment":202},{"nctId":"NCT00707889","phase":"PHASE2","title":"Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-10","conditions":"Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":159},{"nctId":"NCT00070122","phase":"PHASE3","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":2200},{"nctId":"NCT00609622","phase":"PHASE2","title":"Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Colorectal Neoplasms","enrollment":191},{"nctId":"NCT00118261","phase":"PHASE1","title":"Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-03","conditions":"Colorectal Cancer","enrollment":17},{"nctId":"NCT00779311","phase":"PHASE1","title":"A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2008-10","conditions":"Metastatic Colorectal Cancer","enrollment":8},{"nctId":"NCT00988897","phase":"PHASE2","title":"Colorectal Cancer RECHALLENGE","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2009-10","conditions":"Colorectal Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mFOLFOX6-bevacizumab","genericName":"mFOLFOX6-bevacizumab","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}